About
CAR-T immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyChina
Team (1)
Clinical Trials (36)
View allTotal Trials
36
As Lead Sponsor
13
As Collaborator
23
Total Enrollment
3,126
By Phase
EARLY_PHASE1: 5PHASE1: 15PHASE1/PHASE2: 6NA: 8
By Status
UNKNOWN: 10RECRUITING: 9ACTIVE_NOT_RECRUITING: 6COMPLETED: 6NOT_YET_RECRUITING: 5
Clinical Trials Pipeline36 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT06730256Collaborator
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
EARLY_PHASE1Recruiting
24 participants
Started: Jul 23, 2025 · Completed: Dec 31, 2027
NCT07033299Collaborator
The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
PHASE1Not yet recruiting
12 participants
Started: Jul 1, 2025 · Completed: Mar 31, 2027
NCT06988059Collaborator
A Study of CT0596 in Plasma Cell Leukemia
EARLY_PHASE1Recruiting
27 participants
Started: Jun 25, 2025 · Completed: Dec 31, 2027
NCT07031713Collaborator
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
PHASE1Not yet recruiting
12 participants
Started: Jun 16, 2025 · Completed: Mar 31, 2027
NCT06825845Lead Sponsor
Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
N/ANot yet recruiting
1,500 participants
Started: Mar 31, 2025 · Completed: Jun 30, 2040
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...